Immune-Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer With Uncommon Histology

•Efficacy of Immune-checkpoint inhibitors (ICIs) in non-small cell lung cancer with uncommon histology is an unmet need.•Our findings highlight no progression-free survival and overall survival difference compared to common histotypes•Further prospective trials are needed to clarify ICIs role in unc...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical lung cancer 2022-01, Vol.23 (1), p.e17-e28
Hauptverfasser:	Manglaviti, Sara, Brambilla, Marta, Signorelli, Diego, Ferrara, Roberto, Lo Russo, Giuseppe, Proto, Claudia, Galli, Giulia, De Toma, Alessandro, Occhipinti, Mario, Viscardi, Giuseppe, Beninato, Teresa, Zattarin, Emma, Bini, Marta, Lobefaro, Riccardo, Massa, Giacomo, Bottiglieri, Achille, Apollonio, Giulia, Sottotetti, Elisa, Di Mauro, Rosa Maria, Trevisan, Benedetta, Ganzinelli, Monica, Fabbri, Alessandra, de Braud, Filippo G.M., Garassino, Marina Chiara, Prelaj, Arsela
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Aged, 80 and over Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - pathology Female Humans ICIs Immune Checkpoint Inhibitors - pharmacology Immunotherapy Kaplan-Meier Estimate Lung cancer Lung Neoplasms - drug therapy Lung Neoplasms - pathology Male Middle Aged Proportional Hazards Models Rare histology Retrospective Studies Survival Analysis Uncommon NSCLC
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!